Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.750-7.000 for the period, compared to the consensus estimate of 6.310. The company issued revenue guidance of $49.0 billion-$50.0 billion, compared to the consensus revenue estimate of $47.3 billion.

Bristol Myers Squibb Stock Performance

Shares of BMY traded up $1.88 during trading hours on Thursday, hitting $64.98. The company had a trading volume of 18,018,696 shares, compared to its average volume of 12,268,565. The firm has a market cap of $132.70 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.18 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business has a fifty day moving average of $57.90 and a 200-day moving average of $58.29. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $65.56.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm posted $1.46 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Weiss Ratings cut Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Bank of America decreased their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Raymond James Financial reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.25.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Quarterly results exceeded expectations. BMY reported adjusted earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue rose 5.7% year over year to $12.97 billion, well ahead of the $11.74 billion forecast. Earnings also increased from $1.46 per share in the prior-year quarter. Reuters article
• Positive Sentiment: Management raised its 2026 outlook. The company now expects adjusted EPS of $6.75–$7.00 and revenue of $49 billion–$50 billion, above analyst expectations of approximately $6.31 EPS and $47.3 billion in revenue. Wall Street Journal article
• Positive Sentiment: Growth products are helping offset patent-related pressure. Strong demand for Eliquis, along with newer treatments including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, supported the quarter. Investors are increasingly focused on whether these products can replace declining legacy-drug revenue. Quartz article
• Positive Sentiment: Valuation remains attractive to some analysts. A bullish view highlighted BMY’s low forward valuation and roughly 4% dividend yield, while Piper Sandler maintained a Buy rating. Seeking Alpha article
• Neutral Sentiment: Analyst opinion remains mixed: strong results and a better Eliquis outlook were balanced by a Hold rating reflecting legacy-product declines and delays or uneven performance among pipeline assets. TipRanks article
• Negative Sentiment: Put-option trading was unusually heavy, with 44,620 puts purchased—about 77% above average—signaling that some traders are hedging against a pullback or taking a bearish view despite the earnings beat.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $25,000. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the third quarter worth $36,000. Turning Point Benefit Group Inc. bought a new stake in Bristol Myers Squibb in the third quarter valued at $40,000. Finally, Quarry LP acquired a new position in shares of Bristol Myers Squibb during the third quarter valued at about $48,000. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.